Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Some new projects will study viral persistence, including one that will test the HIV meds Truvada and maraviroc.
Nirsevimab, a monoclonal antibody, is one of two new therapies that could dramatically reduce the risk of lung infections in infants.
Funding includes $1 billion for vaccine trials, $326 million for a new monoclonal antibody and $100 million for novel technologies.
The monoclonal antibody combo is used as pre-exposure prophylaxis for immunocompromised people who may not respond to COVID-19 vaccines.
EBV is associated with certain cancers, including Hodgkin lymphoma, and autoimmune diseases, such as multiple sclerosis.
Get a COVID booster, especially if you’re older or your immune system is compromised, and don’t forget the flu shot.
People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.
Cancer patients undergoing treatment and those with suppressed immune systems eye the future—and the COVID pandemic’s wane—warily.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
NIAID director Anthony Fauci, MD, and coauthors emphasize the need for a global response to COVID-19.
Certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
Even as drugmakers ramp up supplies, only a trickle of the product has found its way into regular people.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.